Mounjaro / Zepbound (generic Tirzepatide)

Beskrivelse

Generic Description (Research Reagent Use Case)

Product Name: Tirzepatide (synthetic peptide)

CAS Number: 2023788-19-2

Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

Molecular Weight: approximately 4813.45

Description: Tirzepatide is a 39-amino acid synthetic peptide and a dual agonist of the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors . It is commonly supplied as a lyophilized powder (acetate salt form) and is intended for laboratory research use only .

Purity: typically ≥95% (HPLC)

Storage Conditions: Store at -20°C, protected from light, avoid repeated freeze-thaw cycles

Use Restrictions: For research use only, not for diagnostic, therapeutic, or in vivo use .

Generic Description (Pharmaceutical Product Use Case, based on Mounjaro/Zepbound)

Active Ingredient: Tirzepatide

Mechanism of Action: A dual GIP/GLP-1 receptor agonist that improves glycemic control through multiple pathways including enhanced insulin secretion, delayed gastric emptying, and central appetite regulation .

Approved Indications (varies by region):

• Type 2 diabetes mellitus (as an adjunct to diet and exercise)

• Chronic weight management (for adults with obesity or overweight with at least one weight-related comorbidity)

• Obstructive sleep apnea (OSA)

Dosage Form: Solution for subcutaneous injection, available in single-dose vials or multi-dose prefilled pens (KwikPen) .

Common Specifications: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (single-dose) .

Common Adverse Reactions: Nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, etc. .

Key Contraindications: Personal or family history of medullary thyroid carcinoma (MTC), or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) .

Tirzepatide’s core advantage in weight control lies in its dual receptor agonism mechanism, which produces weight loss effects that, in both clinical trials and real-world data, significantly outperform single GLP-1 receptor agonists (such as semaglutide). Its benefits are primarily reflected in three aspects: stronger magnitude of weight reduction, higher proportion of patients achieving clinically meaningful weight loss thresholds, and preferential fat loss while relatively preserving lean body mass.

Magnitude of Weight Reduction: Significantly Superior to Semaglutide

A systematic review and meta-analysis directly comparing tirzepatide and semaglutide showed that tirzepatide was associated with an additional 4.61% reduction in body weight percentage and an additional 4.76 kg reduction in absolute weight compared to semaglutide. In the SURMOUNT-1 trial, at 72 weeks of treatment, the average weight loss in the 15 mg dose group reached 20.9%, compared to only 3.1% in the placebo group. A real-world study showed that after only 24 weeks of treatment, patients’ average body weight decreased from 95 kg to 80 kg, a reduction of approximately 16%, which was comparable to the weight loss achieved at 72 weeks in the SURMOUNT-1 trial.

Proportion Achieving Weight Loss Thresholds: Dose-Dependent Significant Improvement

In the SURMOUNT-1 trial, the proportion of patients in the 5 mg group achieving ≥5%, ≥10%, and ≥20% weight loss were 85.1%, 68.5%, and 30%, respectively, while the corresponding proportions in the placebo group were only 34.5%, 18.8%, and 3.1%. At higher doses, the proportion achieving ≥25% weight loss reached 36.2% in the 15 mg group. This means that a considerable proportion of patients can achieve substantial weight reduction that far exceeds conventional standards.

Body Composition: Predominantly Fat Loss, Relatively Preserved Muscle

A 12-week real-world bioelectrical impedance analysis study found that approximately 78% of the total weight lost with tirzepatide came from fat mass, with a relatively small decrease in lean soft tissue, and the relative proportion of lean mass actually increased. Another 24-week real-world study also confirmed that fat mass decreased by 35%, while skeletal muscle mass was preserved (not statistically significant). This pattern of “fat loss with muscle preservation” has positive implications for metabolic health.

Additional Metabolic Benefits

In addition to weight reduction itself, tirzepatide also improves multiple metabolic indicators. The real-world study showed that HbA1c decreased from 5.5% to 5.2%, fasting insulin dropped from 17 to 12 μIU/mL, and HOMA-IR (insulin resistance index) decreased from 4.2 to 2.5. The official FDA label also lists tirzepatide for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.

It should be noted that the above data primarily come from clinical trials and real-world observational studies of brand-name tirzepatide products (Zepbound/Mounjaro), and there are no independent studies on the efficacy of generic products. Additionally, all trials were conducted under the premise of combined calorie restriction and increased physical activity.